TAIMED BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.7 TWD | -1.48% |
|
+1.40% | +5.73% |
ETFs positioned on TaiMed Biologics Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 2 M€ | -.--% | ||
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 0 M€ | +3.30% | - | |
| 0.00% | 0 M€ | +3.53% | - |
TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
86.7
TWD
Average target price
133.7
TWD
Spread / Average Target
+54.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.73% | 731M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +7.77% | 23.47B | |
| -13.89% | 21.9B | |
| -5.99% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- 4147 Stock
- Funds and ETFs TaiMed Biologics Inc.
